Citations

Clear

7552 citation(s) found for "Ho, Matthew".

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study)
Starling, Amaal J. , Tepper, Stewart J. , Marmura, Michael J. , Shamim, Ejaz A. , Hindiyeh, Nada , Charles, Andrew , Goadsby, Peter J. , Silberstein, Stephen D., Gelfand, Amy A. , Chiacchierini, Richard P., Goadsby, Peter J , Marmura, Michael J , Robbins, Matthew S. , Lipton, Richard B. , Dodick, David W. , Charles, Andrew , Gelfand, Amy A

Mayo Clinic

Cephalalgia | March 5, 2018 | Volume: 38 | Issue: 6 | Pages: 1038-1048

10.1177/0333102418762525 | PMID 29504483 Get It

Objective To evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine. Background sTMS was originally developed for the acute treatment of migraine with aura. Open label experience has suggested a preventive benefit. The objective of this trial was to evaluate the efficacy and tolerability of sTMS for migraine prevention. Methods The eNeura SpringTMS Post-Market Observational U.S. Study of Migraine (ESPOUSE) Study was a multicenter, prospective, open label, observational study. From December 2014 to March 2016, patients with migraine (n = 263) were consented to complete a 1-month baseline headache diary followed by 3 months of treatment. The treatment protocol consisted of preventive (four pulses twice daily) and acute (three pulses repeated up to three times for each attack) treatment. Patients reported daily headache status, medication use, and device use with a monthly headache diary. The primary endpoint, mean reduction of headache days compared to baseline, was measured over the 28-day period during weeks 9 to 12. The primary endpoint was compared to a statistically-derived placebo estimate (performance goal). Secondary endpoints included: 50% responder rate, acute headache medication consumption, HIT-6, and mean reduction in total headache days from baseline of any intensity. Results Of a total of 263 consented subjects, 229 completed a baseline diary, and 220 were found to be eligible based on the number of headache days. The device was assigned to 217 subjects (Safety Data Set) and 132 were included in the intention to treat Full Analysis Set. For the primary endpoint, there was a −2.75 ± 0.40 mean reduction of headache days from baseline (9.06 days) compared to the performance goal (−0.63 days) ( p < 0.0001). The 50% responder rate of 46% (95% CI 37%, 56%) was also significantly higher ( p < 0.0001) than the performance goal (20%). There was a reduction of −2.93 (5.24) days of acute medication use, headache impact measured by HIT-6, −3.1 (6.4) ( p < 0.0001), and total headache days of any intensity −3.16 days (5.21) compared to the performance goal (−0.63 days) ( p < 0.0001). The most common adverse events were lightheadedness (3.7%), tingling (3.2%), and tinnitus (3.2%). There were no serious adverse events. Conclusions This open label study suggests that sTMS may be an effective, well-tolerated treatment option for migraine prevention. Trial registration number NCT02357381
Endoscopic Resection of a Paraclinoid Meningioma Extending Into the Optic Canal: 2-Dimensional Operative Video
Abi-Aad, Karl R., Sattur, Mithun G. , Welz, Matthew E., Hoxworth, Joseph M. , Bendok, Bernard R. , Lal, Devyani

Mayo Clinic

Operative Neurosurgery | March 3, 2018 | Volume: 15 | Issue: 3 | Pages: 356-356

10.1093/ons/opy011 | PMID 29514297 Get It

Bilateral Corneal Deposits 1 Week After Starting Oral Prednisone Therapy
Starr, Matthew R. , Maguire, Leo J., Salomão, Diva R. , Starr, Matthew R

Mayo Clinic

JAMA Ophthalmology | March 1, 2018 | Volume: 136 | Issue: 5 | Pages: 591

10.1001/jamaophthalmol.2017.5316 | PMID 29494722 Get It

A19 BACTERIAL PROTEASES INCREASE SENSITIVITY TO DIETARY ANTIGEN THROUGH PAR-2 SIGNALING
Fernandez, A Caminero, Bernier, Steve P., Blanco, Jorge, Surette, Matthew D., Fernández, Alberto Caminero, McCarville, Justin L. , Galipeau, Heather J. , Deraison, Céline , Murray, Joseph A. , Coombes, Brian K. , Ruf, Wolfgang Philipp , Vergnolle, Nathalie , Verdú, Elena F.

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 1, 2018 | Volume: 1 | Issue: suppl_2 | Pages: 31-32

10.1093/jcag/gwy009.019 Get It

Creation of a tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma.
Bhindi, Bimal , Lohse, Christine M. , Cheville, John C. , Mason, Ross , Tollefson, Matthew K. , Harrington, Susan M. , Parker, Alexander S. , Boorjian, Stephen A. , Thompson, R. Houston, Leibovich, Bradley C. , Dong, Haidong

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: 703-703

10.1200/jco.2018.36.6_suppl.703 Get It

703 Background: Clinical and pathologic factors alone have limited prognostic ability in patients with metastatic clear cell renal cell carcinoma (ccRCC). We sought to determine if tissue biomarkers, along with our previously reported clinical metastases score, can be used to predict cancer specific survival (CSS) in patients with metastatic ccRCC. Methods: Patients with metastatic ccRCC who underwent nephrectomy between 1990-2004 were identified using the Mayo Clinic Nephrectomy Registry. Sections from paraffin-embedded primary tumor tissue blocks were used for immunohistochemistry staining for PD-1, B7-H1 (PD-L1), B7-H3, Bim (downstream pro-apoptotic signaling molecule in PD-1 pathway), CA-IX, IMP3, Ki67, and survivin. CSS was the primary outcome. Biomarkers that were significantly associated with CSS after adjusting for the metastases score were used to develop a biomarker-specific multivariable model using a bootstrap resampling approach and forward selection. Predictive ability was summarized using a bootstrap-corrected c-index. Results: The cohort included 602 patients, 192 (32%) with metastases at diagnosis and 410 (68%) who developed metastases after nephrectomy. Median follow-up among survivors was 9.6 years (IQR 4.2,12.8) and 504 patients died of RCC. Bim, IMP3, Ki67, and survivin expression were significantly associated with CSS after adjusting for the metastases score and were used to develop a biomarker-specific model. High Bim (HR 1.44; 95%CI 1.16-1.78; p < 0.001), high survivin (HR 1.35; 95%CI 1.08-1.68; p = 0.008), and the metastases score (HR 1.13 per one point; 95%CI 1.10-1.16; p < 0.001) were retained as independent predictors in the final multivariable model (c-index 0.69). Conclusions: We created a prognostic model combining the clinical metastases score and two primary tissue expression biomarkers, Bim and survivin, for patients with metastatic RCC who underwent nephrectomy. External validation will be required prior to clinical use.
Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis.
Tendulkar, Rahul D. , Niemierko, Andrzej , Stephans, Kevin L. , Lee, W. Robert , Michalski, Jeff M. , Pisansky, Thomas M. , Pollack, Alan , Zietman, Anthony L., Stephenson, Andrew J. , Hwang, William L. , Agrawal, Shree , Spratt, Daniel E. , Hearn, Jason W.D. , Koontz, Bridget F. , Liauw, Stanley L. , Abramowitz, Matthew C. , Moghanaki, Drew M. , Anscher, Mitchell S. , Den, Robert B. , Efstathiou, Jason A.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: 24-24

10.1200/jco.2018.36.6_suppl.24 Get It

24 Background: The use of radical prostatectomy (RP) as initial treatment of high-risk/locally-advanced prostate cancer is increasing but patients (pts) with adverse pathologic features such as positive surgical margins or T3 disease have up to 70% recurrence risk. These high-risk pts may be managed with adjuvant radiotherapy (ART) or early salvage radiotherapy (ESRT). The optimal timing of post-operative radiotherapy is unclear. Methods: Individual data from 1566 consecutive pts with pT2N0M0/R1 or pT3N0M0/R0-1 disease who underwent post-prostatectomy ART or ESRT (1987-2013) at 10 academic centers were pooled. Post-irradiation freedom from biochemical failure (FFBF), freedom from distant metastases (FFDM), prostate-cancer specific survival (PCSS), and overall survival (OS) were compared using Kaplan-Meier and multivariate competing-risks regression (MVA) analyses. Propensity score (PS) matching was used to account for covariates potentially associated with treatment allocation. All outcomes were measured from the date of surgery to address lead time bias. Results: After PS-matching, median follow-up after surgery was 66 vs. 73 months for the ART and ESRT groups, respectively, and baseline characteristics were well-matched. ART was associated with higher FFBF (12-yr: 69% vs. 43%; log-rank P < 0.0001), FFDM (12-yr: 95% vs. 85%; log-rank P = 0.03), PCSS (12-yr: 99% vs. 94%; log-rank P = 0.048), and OS (12-yr: 91% vs. 79%; log-rank P = 0.01). ART, lower Gleason score, lower T-stage, nodal irradiation, and postoperative androgen deprivation therapy were favorable prognostic features on MVA for BF. Sensitivity analysis demonstrated that the decreased risk of BF associated with ART remained significant unless more than 56% of ART pts were cured by surgery alone. This threshold is greater than the estimated 12-yr FFBF of 46% after RP alone as determined by a contemporary nomogram. Conclusions: To the best of our knowledge, this represents the largest multi-institutional study to date comparing ART to ESRT. ART was associated with reduced biochemical recurrence, distant metastases, and death compared to ESRT for high-risk pts, pending prospective validation.
Tumor-infiltrating lymphocytes in androgen receptor-positive, triple-negative breast cancer.
Leon‐Ferre, Roberto A. , Polley, Mei‐Yin C. , Liu, Heshan , Cafourek, Victoria, Negron, Vivian , Liu, Minetta C. , Visscher, Daniel W., Boughey, Judy C. , Kalari, Krishna R. , Ingle, James N. , Couch, Fergus J. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 5_suppl | Pages: 5-5

10.1200/jco.2018.36.5_suppl.5 Get It

5 Background: Triple-negative breast cancer (TNBC) is an immunogenic breast cancer subtype, with a greater percentage of tumors containing tumor-infiltrating lymphocytes (TILs) compared to non-TNBC. TILs are prognostic for recurrence and predictive for chemotherapy benefit in TNBC, but not in estrogen receptor (ER)-positive tumors. A subset of TNBC expresses the androgen receptor (AR), and resembles ER-positive breast cancer in terms of demographics (older age) and clinical course (later recurrences that tend to involve bone). However, little is known regarding the association between TILs and AR expression in TNBC. Methods: From a cohort of 9982 women with surgically-treated non-metastatic breast cancer, patients who met criteria for TNBC (ER/PR < 1% and HER2-negative) by centralized-pathology review were included as previously published [Leon-Ferre et al, Breast Cancer Res Treat 2017]. Stromal TILs in these tumors were quantified on full-face hematoxylin and eosin sections from the surgical specimen, following the 2014 TIL Working Group recommendations [Salgado et al, Ann Oncol 2014]. The expression of AR [EPR1535(2), Abcam] was scored as a continuous variable (1% increments), and categorized as absent (0%), low (1-25% ), low-moderate (26-50%) moderate (51-75%) and high (> 75%) and correlated with TIL density. Results: 605 patients met criteria for TNBC. The median age was 56 years. Most tumors were T1-2 (95%), N0-1 (86%), and high grade (88%). The median stromal TIL content was 20% (0-90%). Tumor tissue was available for AR staining in 509/605 patients. 165 (32%) tumors expressed AR as follows: low: 12%, low-moderate: 7%, moderate: 5%, and high: 8%. Apocrine tumors (n = 30) expressed AR most frequently (86%) and at higher levels (AR high: 50%). For all 509 tumors, the median stromal TIL content according to AR expression was AR absent: 20%, AR low: 20%, AR low-moderate: 15%, AR high: 10%. AR and stromal TILs (both as continuous variables) demonstrated a weak inverse correlation (correlation coefficient -0.1064, p = 0.017). Conclusions: AR expression in TNBC is associated with lower levels of stromal TILs. Additional data correlating the AR, stromal TILs and outcomes in this cohort will be presented at the meeting.
Validation of a dynamic joint contracture measuring device in a live rabbit model of arthrofibrosis
Reina, Nicolas , Trousdale, William H. , Salib, Christopher G. , Evertz, Loribeth Q., Berglund, Lawrence J., Wijnen, André J. van , Hewett, Timothy E. , Berry, Daniel J., Berry, Daniel J. , Berry, Charlotte E. , Sanchez-Sotelo, Joaquin, van Wijnen, Andre J , Berry, Daniel J , Berry, Daniel J., Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Abdel, Matthew P.

Mayo Clinic

Journal of Orthopaedic Research | February 23, 2018 | Volume: 36 | Issue: 8 | Pages: 2186-2192

10.1002/jor.23884 | PMID 29473666 Get It

ABSTRACTThe current method of measuring arthrofibrosis in live rabbits is critically limited. Specifically, this method involves radioactive fluoroscopy, error‐prone goniometric measurements, and static joint angle outcomes that fail to approximate the compliance of tissues surrounding the joint. This study aims to validate a novel method of capturing the compliance of contracted tissues surrounding the joint without the use of fluoroscopy or animal sacrifice. Surgically induced contractures of one‐hundred and eight rabbits were measured using the current standard of contracture measurement (a pulley system) as well as a newly designed dynamic load cell (DLC) device. The DLC device was highly reliable when compared to the pulley system (r = 0.907, p < 0.001). Finally, the DLC device produced joint stiffness hysteresis curves capable of approximating the compliance of stiff joint tissues, ultimately calculating a mean joint stiffness of 1.57 ± 1.31 N · m · rad−1 (range, 0.33–6.37 N · m · rad−1). In conclusion, the DLC device represents a valid method for measuring joint contractures. Further, the DLC device notably improves current techniques by introducing the capacity to approximate the compliance of contracted tissues in living rabbits. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:2186–2192, 2018.
Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital ( SEARCH ) database
Herforth, Christine, Stroup, Sean P. , Chen, Zinan, Howard, Lauren E. , Freedland, Stephen J. , Amling, Christopher L. , Moreira, Daniel M. , Terris, Martha K. , Aronson, William J. , Cooperberg, Matthew R , Kane, Christopher J. , Howard, Lauren E , Stroup, Sean P

Mayo Clinic

BJU International | February 23, 2018 | Volume: 122 | Issue: 4 | Pages: 592-598

10.1111/bju.14178 | PMID 29473992 Get It

Objective To evaluate biochemical recurrence ( BCR ) patterns amongst men undergoing radical prostatectomy ( RP ) with specimens having negative ( NSM ), positive ( PSM ), and close surgical margins ( CSM ) from the Shared Equal Access Regional Cancer Hospital ( SEARCH ) cohort, as PSM after RP are a significant predictor of biochemical failure and possible disease progression, with CSM representing a diagnostic challenge for surgeons. Patients and Methods Men undergoing RP between 1988 and 2015 with known final pathological margin status were evaluated. The cohort was divided into three groups based on margin status; NSM , PSM , and CSM . CSM were defined by distance of tumour ≤1 mm from the surgical margin. BCR was defined as a prostate‐specific antigen ( PSA ) level of >0.2 ng/mL, two values at 0.2 ng/mL, or secondary treatment for an elevated PSA level. Predictors of BCR , metastases, and mortality were analysed using Cox proportional hazard models. Results Of 5515 men in the SEARCH database, 4337 (79%) men met criteria for inclusion in the analysis. Of these, 2063 (48%) had NSM , 1902 (44%) had PSM , and 372 (8%) had CSM . On multivariable analysis, relative to NSM , men with CSM had a higher risk of BCR (hazard ratio [ HR ] 1.51, 95% confidence interval [ CI ] 1.25–1.82; P < 0.001) but a decreased risk of BCR when compared to those men with PSM ( HR 2.09, 95% CI 1.86–2.36; P < 0.001). Metastases, prostate cancer‐specific mortality and all‐cause mortality did not differ based on margin status alone. Conclusions Management of men with CSM is a diagnostic challenge, with a disease course that is not entirely benign. The evaluation of other known risk factors probably provides greater prognostic value for these men and may ultimately better select those who may benefit from adjuvant therapy.